TRM - 359 (etoricoxib) is being developed as a breakthrough, first approved treatment for a serious pediatric orphan disease for which high-potency opioid therapies are the only available therapies.

  • In discussions with FDA regarding the proposed clinical development plan for TRM - 359

  • Targeting pediatric population to avoid opioid exposure in young patients

  • Preparing to file multiple orphan designations

  • Anticipating fast-track or break-through therapy status

  • Additional follow-on indications are being explored